SLU-PP-332-PLUS 500mcg 60 caps

What is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule that activates all three estrogen-related receptors (ERRα, ERRβ and ERRγ), with the highest potency at ERRα. In the cell, these receptors control the genes on which mitochondrial function and fatty acid oxidation depend. Thomas Burris’s team described it in 2023 as an agonist with pharmacokinetic properties sufficient for studies in animals (Billon et al., 2023).

Data on SLU-PP-332 come from cell cultures and from mouse models of obesity (Billon et al., 2024), heart failure (Xu et al., 2024) and kidney aging (Wang et al., 2023). There are no clinical studies in humans: ClinicalTrials.gov lists no study of this compound (as of 27 October 2026). Chemical reagent intended exclusively for laboratory research (Research Use Only). It is not a medicinal product, dietary supplement or food, and it is not intended for use in humans or animals.

Are you looking for a different type of SLU-PP-332? Check out our versions 100mcg and 1000mcg. 

In the context of scientific research, SLU-PP-332 is a valuable model to study:

• Mitochondrial processes in cells
• Mechanisms of regulation of energy metabolism
• Signaling pathways associated with nuclear receptors
• Mitochondrial biogenesis
• Oxidation of energy substrates

Scientific context

ERR receptors (ERRα, ERRβ, ERRγ) belong to the family of nuclear receptors and play an important role in regulating the expression of genes related to energy metabolism. In vitro studies have shown that SLU-PP-332 has agonist properties towards these receptors, which makes it a useful tool in basic research on the functioning of these molecular pathways.

INTENDED FOR RESEARCH PURPOSES! All the above-mentioned properties are observed in laboratory tests, not performed on humans, they are for information purposes only. All information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a medicine, food product or dietary supplement and is therefore not suitable for human consumption.

The product qualifies as a chemical reagent/reference material authorized for marketing in the EU. It can only be used for scientific research. Other information about the agent is included in the safety data sheet for the chemical substance, which we make available for viewing. Products are available only to institutions or private individuals associated with research or laboratory activities. As a compound with no marketing authorisation in any country, SLU-PP-332 falls under class S0 of the 2026 WADA Prohibited List (non-approved substances) and is prohibited at all times. From 1 January 2027, the List names it in class S4, and it remains prohibited at all times — professional athletes and persons covered by anti-doping programs check the current version of the List on their own.

SLU-PP-332 is a synthetic organic compound classified as a research chemical. In chemical nomenclature, it is a small organic molecule designed to selectively activate ERR receptors.

Key information:

• Legal status: Chemical reagent/reference material
• Intended use: laboratory research only (Research Use Only)
• Form: Capsules containing 500mcg of active substance
• Packaging: 60 capsules

SLU-PP-332 is an organic compound with a specific chemical structure, designed to selectively interact with ERR receptors. Detailed molecular structure and spectroscopic data are available in the chemical safety data sheet (SDS).

Mechanism of molecular interaction

Based on scientific publications, SLU-PP-332 in in vitro tests shows the ability to:

• Binding to the ligand-binding domain of ERR receptors
• Induction of conformational changes in the receptor structure
• Modulation of transcriptional coactivator recruitment
• Effects on the expression of ERR target receptor genes

These properties make it a useful tool in research on the molecular mechanisms of energy metabolism regulation.

Interaction with ERR receptors

In vitro studies have shown that SLU-PP-332 acts as an agonist of ERR receptors. This mechanism includes the following steps at the molecular level:

1. Receptor binding:

SLU-PP-332 binds to the Ligand Binding Domain (LBD) of ERR receptors, especially ERRα and ERRγ. This binding induces conformational changes in the receptor structure.

2. Transcriptional activation:

After binding the ligand, the ERR receptor is activated and increases its ability to recruit transcriptional coactivators, such as PGC-1α (Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha).

3. Regulation of gene expression:

The activated receptor-coactivator complex binds to ERR response elements (ERRE) in the promoter regions of target genes, modulating their expression.

4. Target genes:

In vitro studies have identified numerous genes whose expression is modulated by activation of ERR receptors, including genes related to:

• Mitochondrial metabolism
• Oxidation of fatty acids
• Mitochondria respiratory chain
• Mitochondrial biogenesis

Observations in cell models

In experiments conducted on in vitro cell lines, it was observed that treatment of cells with SLU-PP-332 leads to:

• Increased mitochondrial gene expression
• An increase in the number of mitochondria in cells
• Increased activity of respiratory chain enzymes
• Changes in the metabolic profile of cells

These observations constitute the basis for further research on the role of ERR receptors in the regulation of cellular metabolism.

Basic research on metabolism

SLU-PP-332 is used as a research tool in studies on the fundamental mechanisms of energy metabolism regulation. Example areas of research include: Mitochondria Studies:

• Study of mitochondrial biogenesis processes
• Analysis of mitochondrial function in various cell types
• Studies on mitochondrial dynamics (fusion, fragmentation)
• Testing ATP production and oxidative phosphorylation efficiency

Metabolism of energy substrates:

• Fatty acid oxidation analysis
• Studies on glucose metabolism
• Testing the metabolic flexibility of cells
• Analysis of substrate preferences in various conditions

Animal models of metabolic disorders

The scientific literature describes the use of SLU-PP-332 in studies on animal models (mainly rodents) with metabolic disorders: Study by Billon et al. (J Pharmacol Exp Ther, 2024): The publication “A Synthetic ERR Agonist Alleviates Metabolic Syndrome” describes experiments on mice with obesity induced by a high-fat diet. Administration of SLU-PP-332 in these studies was associated with:

• Increased oxidation of fatty acids in tissues
• Reduced accumulation of fat tissue
• Improving metabolic parameters
• Increased expression of mitochondrial genes in muscles

The same study in a University of Florida news release (September 2023): The article “Exercise-mimicking drug sheds weight, boosts muscle activity in mice” described monthly administration of SLU-PP-332 to mice, which resulted in:

• Less weight gain despite identical food intake
• Increased energy expenditure
• Higher metabolic activity of muscles
• Changes in the expression of genes related to metabolism

Research on nuclear receptors

SLU-PP-332 serves as a tool to study the functions and mechanisms of action of ERR receptors:

• Structural studies: Analysis of ligand-receptor interactions using crystallography and molecular modeling methods
• Functional studies: Determining the role of individual ERR isoforms in various tissues
• Signaling pathway analysis: Identification of target genes and interacting partners of ERRs
• Molecular pharmacology: Study of structure-activity relationships for the design of new ligands

Potential research directions

The scientific literature indicates potential areas for further research using SLU-PP-332:

1. Aging research: The role of mitochondria and energy metabolism in the aging process
2. Neurobiology: Mitochondria function in nerve cells and neurodegeneration
3. Experimental cardiology: Energy metabolism in the myocardium
4. Molecular oncology: Cancer cell metabolism (Warburg effect)
5. Exercise physiology: Metabolic adaptations to training at the molecular level

SLU-PP-332-PLUS 500 mcg 60 caps is a high-quality chemical reagent intended exclusively for research applications. The product is a valuable tool for scientists conducting research on: ✓ Energy metabolism at the cellular level – studies on energy production processes in mitochondria ✓ ERR nuclear receptors – research on the mechanisms of transcriptional regulation ✓ Mitochondrial biogenesis – analysis of the processes of formation of new mitochondria ✓ Oxidation of energy substrates – studies on the use of various energy sources by cells ✓ Animal models of metabolic disorders – preclinical studies on rodents ✓ Molecular pharmacology – design and testing of new nuclear receptor ligands Status: Research Use Only; no clinical studies in humans; WADA: prohibited at all times (2026 List: class S0, non-approved substances; from 1 January 2027: class S4, listed by name).

1. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome” – a study on mouse models showed that SLU-PP-332 improved the metabolism of the entire body (including increased fatty acid oxidation, reduced accumulation of adipose tissue) in mice with obesity/metabolic syndrome. A Synthetic ERR Agonist Alleviates Metabolic Syndrome – PubMed 2. The article “Exercise-mimicking drug sheds weight, boosts muscle activity in mice” describes that in mice, administration of SLU-PP-332 for a month resulted in less fat tissue gain and higher energy expenditure, despite the same amount of food.

Exercise-mimicking drug sheds weight, boosts muscle activity in mice News | University of Florida 3. “Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity” – the first description of SLU-PP-332 (Billon et al., ACS Chem Biol, 2023). In a skeletal muscle cell line the compound increased mitochondrial function and cellular respiration, and in mice it increased the share of oxidative type IIa fibers. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity – PubMed